糖尿病性骨质疏松症的治疗进展

Progress in Treatment of Diabetic Osteoporosis

糖尿病性骨质疏松症(DOP)是现代社会常见病,其发病率越来越高。临床治疗DOP主要以治疗糖尿病原发病和治疗骨质疏松为主,在以控制血糖为前提下,抑制骨吸收、促进骨形成、改善骨矿化。他汀类药物对骨质疏松症亦有保护作用,主要表现在能有效改善骨密度,增加骨量。有效的血糖控制与抗骨质疏松药联合应用能有效改善DOP不适症状,增加骨密度,降低骨质疏松性骨折发生风险。但目前对DOP的研究仍较为单一,期待在基因分子水平层面针对本病的发病机制及治疗方法能有更多发现。

Diabetic osteoporosis（DOP） is a common disease of modem society with increasing incidence. The clinical treatment of DOP is mainly from the treatment of diabetes mellitus and osteoporosis,which means with the control of blood sugar as the premise to inhibit bone resorption,promote bone formation, and improve bone mineralization. Statins also have protective effects on osteoporosis, mainly in the effective improvement of bone .mineral density and bone mass. Effective gly- cemic control used in combination with anti-osteoporosis drugs can improve symptoms of DOP and increase bone density and reduce the risk of osteoporotie fractures. But the current study is still undiversified, and more discoveries in the pathogenesis and treatment on the genetic and molecular level are expected.